| Literature DB >> 35717463 |
Jacqueline R Kulbe1, Sonia Jain2, Lindsay D Nelson3, Frederick K Korley4, Pratik Mukherjee5,6, Xiaoying Sun2, David O Okonkwo7, Joseph T Giacino8,9, Mary J Vassar10,11, Claudia S Robertson12, Michael A McCrea3, Kevin K W Wang13, Nancy Temkin14, Christine L Mac Donald14, Sabrina R Taylor10,11, Adam R Ferguson10, Amy J Markowitz10, Ramon Diaz-Arrastia15, Geoffrey T Manley10,11, Murray B Stein16,17,18.
Abstract
Several proteins have proven useful as blood-based biomarkers to assist in evaluation and management of traumatic brain injury (TBI). The objective of this study was to determine whether two day-of-injury blood-based biomarkers are predictive of posttraumatic stress disorder (PTSD). We used data from 1143 individuals with mild TBI (mTBI; defined as admission Glasgow Coma Scale [GCS] score 13-15) enrolled in TRACK-TBI, a prospective longitudinal study of level 1 trauma center patients. Plasma glial fibrillary acidic protein (GFAP) and serum high sensitivity C-reactive protein (hsCRP) were measured from blood collected within 24 h of injury. Two hundred and twenty-seven (19.9% of) patients had probable PTSD (PCL-5 score ≥ 33) at 6 months post-injury. GFAP levels were positively associated (Spearman's rho = 0.35, p < 0.001) with duration of posttraumatic amnesia (PTA). There was an inverse association between PTSD and (log)GFAP (adjusted OR = 0.85, 95% CI 0.77-0.95 per log unit increase) levels, but no significant association with (log)hsCRP (adjusted OR = 1.11, 95% CI 0.98-1.25 per log unit increase) levels. Elevated day-of-injury plasma GFAP, a biomarker of glial reactivity, is associated with reduced risk of PTSD after mTBI. This finding merits replication and additional studies to determine a possible neurocognitive basis for this relationship.Entities:
Year: 2022 PMID: 35717463 DOI: 10.1038/s41386-022-01359-5
Source DB: PubMed Journal: Neuropsychopharmacology ISSN: 0893-133X Impact factor: 8.294